奥曲肽对消化道恶性肿瘤的临床受益反应及其机制探讨

目的 评价奥曲肽治疗晚期消化道恶性肿瘤的临床受益反应(CBR)及其机制。方法 对经组织学或细胞学证实的晚期消化道恶性肿瘤患者31例,采用奥曲肽0.2mg皮下注射,2次/d,连用20 d,综合评估临床受益反应;采用人血管内皮生长因子(VEGF)、胰岛素样生长因子1(IGF-1)定量EIA试剂盒测定其中13例患者治疗前及治疗1周后血清中VEGF、IGF-1,观察奥曲肽对患者血清中VEGF、IGF-1的影响。结果 31例临床受益反应率为48.4%(15/31),13例患者临床受益反应率为46.2%(6/13),VEGF明显下降5例(38.5%),IGF-1明显下降6例(46.2%)。结论 生长抑素类似物奥曲肽能明显降低消化道肿瘤患者血清中VEGF、IGF-1的水平,抑制消化道恶性肿瘤的生长,使患者获得临床受益反应。

CLINICAL-BENEFIT-RESPONSE AND MECHANISMS OF PATIENTS WITH MALIGNANT DIGESTIVE TRACT TUMORS TREATED WITH OCTREOTIDE

Objective:To study the trial investigated clinical-benefit-response and mechanisms of patients with malignant digestive tract tumors treated with octreotide. Methods: 31 patients with malignant digestive tract tumors in the study were histological approved. Octreotide 0.2 mg hypodermic ql2h for 20.The clinical-benefit-response was evaluated. VEGF and IGF-1 in serum were determined by ELISA in 13 of the patients before and after a week of the treatment.The influence of VEGF and IGF-1 in serum of patients with malignant digestive tract tumors treated with octreotide was observed. Results: The clinical-benefit-response was 48.4% (15/31).The clinical-benefit-response of the 13 patients in experiment part was 46.2% (6/13);VEGF in serum was declined in 5 patients (38.5%),IGF-1 in serum was declined in 6 patients (46.2%). Conclusions: Octreotide can decline VEGF and IGF-l's level in serum of patients with malignant digestive tract tumors so as to restrain the growth of the malignant digestive tract tumors, making the clinical-benefit-response to the patients.